The Federal Antimonopoly Service has agreed on the prices of five essential medicines included in the list

The Federal Antimonopoly Service (FAS) has agreed on prices for five essential and essential medicines included in the list. This was reported in the press service of the antimonopoly authority on February 28. Among them are drugs for the treatment of diabetes, antitumor drugs.

"This made it possible to reduce the prices of these drugs by an average of 19% of the average cost of their sale in 2024 and by an average of 141% of the minimum prices in the countries of reference for Russia," the ministry explained.

Such a change will increase their accessibility for Russians. At the same time, they should be provided to citizens free of charge in medical organizations as part of the program of state guarantees of free medical care.

Reference — original — medicinal products with INN "Alogliptin+Pioglitazone, Inclisiran, Alpelisib, Daratumumab and Anifrolumab were included in the list of VED in 2025. The service conducted an economic analysis of the cost, as a result of which it was reduced.

Thus, the prices of Incresinc for the treatment of type 2 diabetes mellitus have been reduced by an average of 28% of the average cost of their sale in 2024 and by an average of 35% of the minimum prices in the countries of reference for Russia. The cost of Sibrava, a cholesterol-lowering drug, has become twice as low as the minimum cost in the reference countries for Russia and 3% lower than the average selling price of the drug in 2024.

The price of the antitumor drug Picray has been halved relative to the minimum cost in the reference countries for Russia and is 16% lower than the average cost of its sale in 2024. The antitumor drug Darzalex, which is intended for the treatment of myeloma, has become twice as cheap as in the reference countries.

The cost of Safnelo, used for the treatment of systemic lupus erythematosus, has been reduced by 37% from the average selling price in 2024 and almost twice from the minimum price in the reference countries for the Russian Federation.

Earlier, on February 5, it was reported that in Russia 540 new medicines have appeared. The total volume of their packages amounted to 52.1 million. This was reported to Izvestia on February 5 in the press service of the Center for the Development of Advanced Technologies (operator of the state marking system "Honest Sign").